

**PERKINS DISCOVERY FUND**

Schedule of Investments

December 31, 2023 (unaudited)

	Shares	Value
<b>99.02% COMMON STOCK</b>		
<b>3.45% BIOTECHNOLOGY</b>		
Journey Medical Corp. <sup>(A)</sup> .....	22,000	\$ 126,720.00
MDxHealth SA <sup>(A)</sup> .....	35,000	137,900
		264,620
<b>8.68% CONSUMER DISCRETIONARY</b>		
Magnite, Inc. <sup>(A)</sup> .....	20,000	186,800
Perion Network Ltd. <sup>(A)</sup> .....	15,500	478,485
		665,285
<b>2.04% FINANCIALS</b>		
FlexShopper, Inc. <sup>(A)</sup> .....	93,500	156,145
<b>24.27% HEALTH CARE DRUGS/SERVICES</b>		
ANI Pharmaceuticals, Inc. <sup>(A)</sup> .....	7,100	391,494
NeoGenomics, Inc. <sup>(A)</sup> .....	22,000	355,960
Veracyte, Inc. <sup>(A)</sup> .....	21,000	577,710
Vericel Corp. <sup>(A)</sup> .....	15,000	534,150
		1,859,314
<b>3.49% HEALTH CARE MANUFACTURING</b>		
AtriCure, Inc. <sup>(A)</sup> .....	7,500	267,675
<b>9.37% HEALTH CARE SUPPLIES</b>		
Axogen, Inc. <sup>(A)</sup> .....	32,500	221,975
BioLife Solutions, Inc. <sup>(A)</sup> .....	15,500	251,875
CryoPort, Inc. <sup>(A)</sup> .....	10,000	154,900
Exagen, Inc. <sup>(A)</sup> .....	16,500	32,835
Perspective Therapeutics, Inc. <sup>(A)</sup> .....	140,923	56,651
		718,236
<b>14.28% HEALTH CARE SUPPORT</b>		
Natera, Inc. <sup>(A)</sup> .....	11,000	689,040
Option Care Health, Inc. <sup>(A)</sup> .....	11,000	370,590
Rockwell Medical, Inc. <sup>(A)</sup> .....	18,181	34,362
		1,093,992

**PERKINS DISCOVERY FUND**

Schedule of Investments - continued

December 31, 2023 (unaudited)

	Shares	Value
<b>4.74% HEALTH CARE TECHNOLOGY</b>		
Fortress Biotech, Inc. <sup>(A)</sup> .....	4,633	\$ 13,945
OptimizeRX Corp. <sup>(A)</sup> .....	14,000	200,340
Streamline Health Solutions, Inc. <sup>(A)</sup> .....	131,500	55,888
Tactile Systems Technology, Inc. <sup>(A)</sup> .....	6,500	92,950
		363,123
<b>15.22% INFORMATION TECHNOLOGY</b>		
Airgain, Inc. <sup>(A)</sup> .....	15,500	55,180
Akoustis Technologies, Inc. <sup>(A)</sup> .....	29,000	24,186
Cantaloupe, Inc. <sup>(A)</sup> .....	43,000	318,630
Digi International, Inc. <sup>(A)</sup> .....	11,000	286,000
Inuvo, Inc. <sup>(A)</sup> .....	514,500	218,662
Perficient, Inc. <sup>(A)</sup> .....	4,000	263,280
		1,165,938
<b>13.48% SOFTWARE SERVICES</b>		
Asure Software, Inc. <sup>(A)</sup> .....	33,000	314,160
ePlus, Inc. <sup>(A)</sup> .....	9,000	718,560
		1,032,720
<b>99.02% TOTAL COMMON STOCK</b> .....		<b>\$7,587,048.00</b>
<b>0.50% SHORT-TERM INVESTMENTS</b>		
Fidelity Government Portfolio 5.250% <sup>(B)</sup> ...	38,361	38,361
		38,361
<b>99.52% TOTAL INVESTMENTS</b> .....		<b>7,625,409</b>
<b>0.48% Assets net of liabilities</b> .....		<b>36,688</b>
<b>100.00% NET ASSETS</b> .....		<b>\$ 7,662,097</b>

<sup>(A)</sup> Non-income producing

<sup>(B)</sup> Effective 7 day yield as of December 31,2023

**PERKINS DISCOVERY FUND**

**Schedule of Investments - continued**

**December 31, 2023 (unaudited)**

In accordance with U.S. GAAP, “fair value” is defined as the price that a Fund would receive upon selling an investment in an orderly transaction to an independent buyer in the principal or most advantageous market for the investment. Various inputs are used in determining the value of a Fund’s investments. U.S. GAAP established a three-tier hierarchy of inputs to establish a classification of fair value measurements for disclosure purposes. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund’s investments as of December 31, 2023:

	Level 1	Level 2	Level 3	Total
	Quoted Prices	Other Significant Observable Inputs	Significant Unobservable Inputs	
Common Stocks . . . . .	\$7,587,048	\$ —	\$ —	\$7,587,048
Short-Term Investments . . . . .	38,361	—	—	38,361
Total Investments . . . . .	\$7,625,409	\$ —	\$ —	\$7,625,409

The Fund held no Level 3 securities at any time during the period.

There were no transfers into or out of Levels 1 and 2 during the period ended December 31, 2023.

At December 31, 2023, the cost of investments for Federal income tax purposes has been estimated since the final tax characteristics cannot be determined until fiscal year end. Cost of securities for Federal income tax purpose is \$4,971,584 and the related tax-based net unrealized appreciation (depreciation) consists of:

Gross unrealized appreciation . . . . .	\$ 4,255,782
Gross unrealized depreciation . . . . .	(1,601,957)
Net unrealized appreciation . . . . .	\$ 2,653,825